128TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases

E Hamilton,J Ramos,W Feng,I Krop

doi:10.1016/j.annonc.2021.03.142

128TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases

E Hamilton, J Ramos + Show 2 more

Open Access

https://doi.org/10.1016/j.annonc.2021.03.142

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: May 1, 2021
Citations: 1	License type: publisher-specific-oa

Affiliation: Tennessee Oncology, Sarah Cannon, Seagen (United States), Dana-Farber Cancer Institute

#Small Molecule Tyrosine Kinase Inhibitor #Combination Of Tucatinib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Tucatinib (TUC) is an oral, reversible, small molecule tyrosine kinase inhibitor highly selective for human epidermal growth factor receptor 2 (HER2). In the HER2CLIMB trial (NCT02614794), the combination of TUC + trastuzumab (T) + capecitabine (C) demonstrated statistically significant and clinically meaningful improvement in progression free survival (PFS), overall survival (OS), and PFS in patients (pts) with brain metastases (BM) compared to T + C alone, supporting regulatory approvals internationally for pts with HER2+ metastatic breast cancer (MBC).

Full Text